Effects of diltiazem, a moderate inhibitor of CYP3A4, on the pharmacokinetics of tamsulosin in different CYP2D6 genotypes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effects of diltiazem, a moderate inhibitor of CYP3A4, on the pharmacokinetics of tamsulosin in different CYP2D6 genotypes

Published:2018-05 Issue:5 Volume:41 Page:564-570
ISSN:0253-6269
Container-title:Archives of Pharmacal Research
language:en
Short-container-title:Arch. Pharm. Res.

Author:

Byeon Ji-Yeong,Lee Yun Jeong,Kim Young-Hoon,Kim Se-Hyung,Lee Choong-Min,Bae Jung-Woo,Jang Choon-Gon,Lee Seok-Yong,Choi Chang-Ik

Funder

National Research Foundation of Korea

Publisher

Springer Science and Business Media LLC

Subject

Organic Chemistry,Drug Discovery,Molecular Medicine

Link

http://link.springer.com/article/10.1007/s12272-018-1030-6/fulltext.html

Reference42 articles.

1. Backman JT, Olkkola KT, Aranko K, Himberg JJ, Neuvonen PJ (1994) Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 37:221–225

2. Bleck JS, Thiesemann C, Kliem V, Christians U, Hecker H, Repp H, Frei U, Westhoff-Bleck M, Manns M, Sewing KF (1996) Diltiazem increases blood concentrations of cyclized cyclosporine metabolites resulting in different cyclosporine metabolite patterns in stable male and female renal allograft recipients. Br J Clin Pharmacol 41:551–556

3. Byeon JY, Kim YH, Na HS, Jang JH, Kim SH, Lee YJ, Bae JW, Kim IS, Jang CG, Chung MW, Lee SY (2015) Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites. Arch Pharm Res 38:2083–2091

4. Chaffman M, Brogden RN (1985) Diltiazem: a review of its pharmacological properties and therapeutic efficacy. Drugs 29:387–454

5. Chaudhry SR, Muhammad S, Eidens M, Klemm M, Khan D, Efferth T, Weisshaar MP (2014) Pharmacogenetic prediction of individual variability in drug response based on CYP2D6, CYP2C9 and CYP2C19 genetic polymorphisms. Curr Drug Metab 15(7):711–718

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug–drug interactions with clarithromycin and paroxetine;Archives of Pharmacal Research;2024-04-25

2. PK-TK Considerations of Nasal, Pulmonary and Oral Routes of Administration;Handbook of Pharmacokinetics and Toxicokinetics;2023-07-03

3. Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes;Archives of Pharmacal Research;2022-06

4. Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to CYP2C9 genetic polymorphism;Archives of Pharmacal Research;2022-05

5. Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin to related CYP2D6*10 allele;ARCH PHARM RES;2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3